A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286 in Subjects with Metastatic Uveal Melanoma
A First-in-Human Study Using FHD-286 in Patients with Metastatic Uveal Melanoma
Sponsor: Foghorn
Enrolling: Male and Female Patients
IRB Number: AAAT6095
U.S. Govt. ID: NCT04879017
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This is a first in human study. You will be given an investigational drug called FHD-286. FHD-286 is not approved by the U.S. Food and Drug Administration (FDA) or other regulatory authorities around the world for the treatment of cancer or any other disease. The purpose of this study is to determine the safety and tolerability of FHD-286 when given to patients with metastatic uveal melanoma. The first phase, or escalation phase, of the study will determine the safe dose for the second phase, or expansion phase, of the study. The primary goal of the expansion phase is to further evaluate the safety of the study drug in patients with metastatic UM. This study will also evaluate the behavior of the study drug in the body and in the tumor(s).
Investigator
Richard Carvajal, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with metastatic uveal melanoma? Yes No
Are you willing to comply with scheduled study visits and treatment plans? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162